KLK3 and posterior cortical atrophy: For instance, the recently published 15-year outcomes from the United Kingdom ProtecT trial, which randomized men diagnosed with localized PCa after screening PSA to either active monitoring, prostatectomy or radiotherapy, suggest low PCa-specific mortality (PCSM) regardless of the treatment assigned to patients [2].